

06-10-04

1642
ifw
40



Express Mail No. EV475140529US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jove *et al.*

Confirmation No.: 1344

Serial No.: 09/492,764

Art Unit: 1642

Filed: January 27, 2000

Examiner: Canella, Karen A.

For: INHIBITION OF STAT3 SIGNAL
TRANSDUCTION FOR HUMAN CANCER
THERAPY

Attorney Docket No: 10873-008-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to the references C01-C05 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references C01-C05 are also provided.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of an "Information Disclosure Citation in an Application".

Applicants request that the Examiner review all the references identified on the attached revised PTO Form 1449, and that they be made of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$0.00. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: June 8, 2004

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

By: Joseph P. Cahill 51,523
Joseph P. Cahill (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY DOCKET NO.

10873-008-999

APPLICATION NO

09/492,764

APPLICANT

Jove et al.

FILING DATE

January 27, 2000

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Han et al., 1997, "Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate," Oncology Res. 9:581-587
C02	Han et al., 1996, "Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors," Cancer Res. 56:3859-3861
C03	Liang et al., 1998, "Chemosensitization of glioblastoma cells to bis-dichloroethyl-nitrosourea with tyrphostin AG17," Clin. Cancer Res. 4:773-781
C04	Penar et al., 1997, "Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain," Neurosurgery 40(1):141-151
C05	Zushi et al., 1997, "Role of heparin-binding EGF-related peptides in proliferation and apoptosis of activated <i>ras</i> -stimulated intestinal epithelial cells," Int. J. Cancer 73:917-923

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.